TransCode Therapeutics, Inc.
RNAZ
$1.77
-$0.13-6.61%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 2.54M | 2.22M | 1.76M | 1.40M | 1.66M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 6.23M | 7.33M | 7.24M | 4.56M | 4.22M |
| Operating Income | -6.23M | -7.33M | -7.24M | -4.56M | -4.22M |
| Income Before Tax | -6.75M | -17.55M | -13.22M | -4.86M | -4.28M |
| Income Tax Expenses | 300.00 | 231.30K | 226.10K | -- | -- |
| Earnings from Continuing Operations | -6.75M | -17.79M | -13.44M | -4.86M | -4.28M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -6.75M | -17.79M | -13.44M | -4.86M | -4.28M |
| EBIT | -6.23M | -7.33M | -7.24M | -4.56M | -4.22M |
| EBITDA | -6.21M | -7.30M | -7.19M | -4.56M | -4.21M |
| EPS Basic | -7.17 | -21.28 | -16.49 | -5.82 | -5.13 |
| Normalized Basic EPS | -4.26 | -4.94 | -4.12 | -3.64 | -3.21 |
| EPS Diluted | -7.17 | -21.28 | -16.49 | -5.82 | -5.13 |
| Normalized Diluted EPS | -4.26 | -4.94 | -4.12 | -3.64 | -3.21 |
| Average Basic Shares Outstanding | 957.20K | 917.00K | 913.10K | 833.70K | 833.70K |
| Average Diluted Shares Outstanding | 957.20K | 917.00K | 913.10K | 833.70K | 833.70K |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |